CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionProfit margin is 35.2%, higher than 95% of its Medical Devices peers (median 4.8%)
- FinancialsAltman Z-Score 14.27: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.24%Above 5Y avg (1.99%)
Annual Rate
CNY 1.08Paid annual
Payout Ratio
46.2%Sustainable
Payback Period
44.6 yr
Last Ex-Dividend
Jun 18, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.62BCNY687.04M · vs all stocks (USD)
Trailing P/E
29.16xvs Medical Devices peers
Revenue (TTM)
472.85MCNY70.32M · vs all stocks (USD)
Profit Margin
35.20%vs Medical Devices peers
Beta
0.4800xvs all stocks
52-Week Change
-11.84%vs all stocks
Market Capitalization
4.62BCNY687.04M · vs all stocks (USD)
Enterprise Value
3.68BCNY547.02M · vs all stocks (USD)
Trailing P/E
29.16xvs Medical Devices peers
Forward P/E
25.47xvs Medical Devices peers
Price to Sales (TTM)
10.22xvs Medical Devices peers
Price to Book (MRQ)
2.76xvs Medical Devices peers
Enterprise to Revenue
7.78xvs Medical Devices peers
Enterprise to EBITDA
22.86xvs Medical Devices peers
Gross Margin
66.16%vs Medical Devices peers
Profit Margin
35.20%vs Medical Devices peers
Operating Margin
32.69%vs Medical Devices peers
Return on Assets (TTM)
4.54%vs Medical Devices peers
Return on Equity (TTM)
9.74%vs Medical Devices peers
Revenue (TTM)
472.85MCNY70.32M · vs all stocks (USD)
Revenue per Share (TTM)
4.92CNYUpdated Aug 21, 2026Quarterly Revenue Growth
10.60%vs Medical Devices peers
Gross Profit (TTM)
312.06MCNY46.41M · vs all stocks (USD)
EBITDA (TTM)
153.53MCNY22.83M · vs all stocks (USD)
Net Income (TTM)
166.43MCNY24.75M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
85.30%vs Medical Devices peers
Operating Cash Flow (TTM)
170.24MCNY25.32M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-99.36MCNY-14.78M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.08CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
2.24%vs all stocks
5-Year Average Dividend Yield
1.99%vs all stocks
Payout Ratio
46.24%vs Medical Devices peers
Revenue
462.73MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
156.46MCNYFY2025 · Dec 31, 2025Gross Profit
306.27MCNYFY2025 · Dec 31, 2025Operating Income
133.37MCNY19.83M · vs all stocks (USD)
Pre-tax Income
154.43MCNYFY2025 · Dec 31, 2025Income Tax Expense
16.36MCNYFY2025 · Dec 31, 2025Net Income
138.07MCNYFY2025 · Dec 31, 2025EBIT
155.74MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
180.14MCNYFY2025 · Dec 31, 2025Research & Development
45.12MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
48.59MCNYFY2025 · Dec 31, 2025Other Operating Expenses
6.60MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.21MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.31MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.44CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.44CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
95.88MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
95.88MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
138.07MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
100.69MCNYFY2025 · Dec 31, 2025Free Cash Flow
24.22MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.02BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
138.07MCNYFY2025 · Dec 31, 2025Other Non-cash Items
2.63MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-35.60MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.42MCNYFY2025 · Dec 31, 2025Capital Expenditures
-76.47MCNYFY2025 · Dec 31, 2025Net Acquisitions
-29.65MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.57BCNYFY2025 · Dec 31, 2025Sale of Investments
3.53BCNYFY2025 · Dec 31, 2025Other Investing Activity
50.00KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-143.49MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-76.57MCNYFY2025 · Dec 31, 2025Other Financing Charges
-877.28KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-77.45MCNYFY2025 · Dec 31, 2025Shares Outstanding
95.77MSharesUpdated Aug 21, 2026Float Shares
36.34MSharesUpdated Aug 21, 2026% Held by Insiders
66.23%vs all stocks
% Held by Institutions
1.01%vs all stocks
Total Cash (MRQ)
931.29MCNY138.49M · vs all stocks (USD)
Total Cash per Share (MRQ)
9.68CNYUpdated Aug 21, 2026Total Debt (MRQ)
396.45KCNY58.96K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0002xvs Medical Devices peers
Current Ratio (MRQ)
9.65xvs Medical Devices peers
Book Value per Share (MRQ)
18.25CNYUpdated Aug 21, 2026Total Assets
1.91BCNY283.89M · vs all stocks (USD)
Total Current Assets
1.12BCNYFY2025 · Dec 31, 2025Total Liabilities
216.00MCNYFY2025 · Dec 31, 2025Total Non-current Assets
793.61MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
585.70KCNYFY2025 · Dec 31, 2025Total Current Liabilities
215.42MCNYFY2025 · Dec 31, 2025Cash
1.02BCNYFY2025 · Dec 31, 2025Cash Equivalents
693.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.02BCNYFY2025 · Dec 31, 2025Accounts Receivable
17.10MCNYFY2025 · Dec 31, 2025Inventory
42.21MCNYFY2025 · Dec 31, 2025Accounts Payable
23.84MCNYFY2025 · Dec 31, 2025Short-term Debt
818.38KCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.81MCNYFY2025 · Dec 31, 2025Long-term Debt
236.04KCNYFY2025 · Dec 31, 2025Common Stock (Book)
95.77MCNYFY2025 · Dec 31, 2025Retained Earnings
486.13MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.69BCNY251.77M · vs all stocks (USD)
Treasury Stock
2.43MCNYFY2025 · Dec 31, 202552-Week Low
43.20CNYUpdated Aug 21, 202652-Week High
72.27CNYUpdated Aug 21, 202652-Week Change
-11.84%vs all stocks
Beta
0.4800xvs all stocks
50-Day MA
52.20CNYUpdated Aug 21, 2026200-Day MA
54.31CNYUpdated Aug 21, 2026Avg 10-Day Volume
1.74MSharesUpdated Aug 21, 2026Avg 30-Day Volume
2.07MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
1.73CNYUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 35.2%, higher than 95% of its Medical Devices peers (median 4.8%)Significant
Profit margin: 0.35Industry median: 0.05Industry P95: 0.32Peers compared: 102
Debt-to-equity is 0×, lower than 95% of its Medical Devices peers (median 0.11×)Notable
Debt-to-equity: 0.00Industry median: 0.11Industry P5: 0.00Peers compared: 102
Financial Health
Altman Z-Score 14.27: safe zoneNotable
Altman Z-Score: 14.27
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Science Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BridgeBio Oncology Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Knight Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Keyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xiangxue Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai ShenQi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Qianjiang Yongan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Minsheng Healthcare Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ars Pharmaceuticals Inc
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Jiangsu Hengli Hydraulic Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Halo Microelectronics Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets